AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Go back to AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata| AbbVie (NYSE: ABBV) | Delayed: 265.03 +1.07 (0.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $263.96 | 52 Week High | $68.12 | |||
| Open | $263.07 | 52 Week Low | $50.71 | |||
| Day High | $266.60 | P/E | 57.49 | |||
| Day Low | $261.23 | EPS | $4.61 | |||
| Volume | 1,008,803 | |||||
